Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar 1;24(5):1478-92.
doi: 10.1093/hmg/ddu552. Epub 2014 Nov 6.

Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk

Jodie N Painter  1 Tracy A O'Mara  1 Jyotsna Batra  2 Timothy Cheng  3 Felicity A Lose  1 Joe Dennis  4 Kyriaki Michailidou  4 Jonathan P Tyrer  5 Shahana Ahmed  5 Kaltin Ferguson  1 Catherine S Healey  5 Susanne Kaufmann  1 Kristine M Hillman  1 Carina Walpole  2 Leire Moya  2 Pamela Pollock  6 Angela Jones  3 Kimberley Howarth  3 Lynn Martin  3 Maggie Gorman  3 Shirley Hodgson  7 National Study of Endometrial Cancer Genetics Group (NSECG)CHIBCHA ConsortiumMa Magdalena Echeverry De Polanco  8 Monica Sans  9 Angel Carracedo  10 Sergi Castellvi-Bel  11 Augusto Rojas-Martinez  12 Erika Santos  13 Manuel R Teixeira  14 Luis Carvajal-Carmona  15 Xiao-Ou Shu  16 Jirong Long  16 Wei Zheng  16 Yong-Bing Xiang  17 Australian National Endometrial Cancer Study Group (ANECS)Grant W Montgomery  1 Penelope M Webb  1 Rodney J Scott  18 Mark McEvoy  19 John Attia  20 Elizabeth Holliday  21 Nicholas G Martin  1 Dale R Nyholt  1 Anjali K Henders  1 Peter A Fasching  22 Alexander Hein  23 Matthias W Beckmann  23 Stefan P Renner  23 Thilo Dörk  24 Peter Hillemanns  25 Matthias Dürst  26 Ingo Runnebaum  26 Diether Lambrechts  27 Lieve Coenegrachts  28 Stefanie Schrauwen  28 Frederic Amant  28 Boris Winterhoff  29 Sean C Dowdy  29 Ellen L Goode  30 Attila Teoman  29 Helga B Salvesen  31 Jone Trovik  31 Tormund S Njolstad  31 Henrica M J Werner  31 Katie Ashton  32 Tony Proietto  33 Geoffrey Otton  33 Gerasimos Tzortzatos  34 Miriam Mints  34 Emma Tham  35 RENDOCASPer Hall  36 Kamila Czene  36 Jianjun Liu  37 Jingmei Li  37 John L Hopper  38 Melissa C Southey  39 Australian Ovarian Cancer Study (AOCS)Arif B Ekici  40 Matthias Ruebner  23 Nicola Johnson  41 Julian Peto  42 Barbara Burwinkel  43 Frederik Marme  44 Hermann Brenner  45 Aida K Dieffenbach  45 Alfons Meindl  46 Hiltrud Brauch  47 GENICA NetworkAnnika Lindblom  35 Jeroen Depreeuw  48 Matthieu Moisse  48 Jenny Chang-Claude  49 Anja Rudolph  50 Fergus J Couch  51 Janet E Olson  30 Graham G Giles  52 Fiona Bruinsma  53 Julie M Cunningham  51 Brooke L Fridley  54 Anne-Lise Børresen-Dale  55 Vessela N Kristensen  56 Angela Cox  57 Anthony J Swerdlow  58 Nicholas Orr  59 Manjeet K Bolla  4 Qin Wang  4 Rachel Palmieri Weber  60 Zhihua Chen  61 Mitul Shah  5 Juliet D French  1 Paul D P Pharoah  5 Alison M Dunning  5 Ian Tomlinson  3 Douglas F Easton  62 Stacey L Edwards  1 Deborah J Thompson  5 Amanda B Spurdle  63
Collaborators, Affiliations

Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk

Jodie N Painter et al. Hum Mol Genet. .

Abstract

Common variants in the hepatocyte nuclear factor 1 homeobox B (HNF1B) gene are associated with the risk of Type II diabetes and multiple cancers. Evidence to date indicates that cancer risk may be mediated via genetic or epigenetic effects on HNF1B gene expression. We previously found single-nucleotide polymorphisms (SNPs) at the HNF1B locus to be associated with endometrial cancer, and now report extensive fine-mapping and in silico and laboratory analyses of this locus. Analysis of 1184 genotyped and imputed SNPs in 6608 Caucasian cases and 37 925 controls, and 895 Asian cases and 1968 controls, revealed the best signal of association for SNP rs11263763 (P = 8.4 × 10(-14), odds ratio = 0.86, 95% confidence interval = 0.82-0.89), located within HNF1B intron 1. Haplotype analysis and conditional analyses provide no evidence of further independent endometrial cancer risk variants at this locus. SNP rs11263763 genotype was associated with HNF1B mRNA expression but not with HNF1B methylation in endometrial tumor samples from The Cancer Genome Atlas. Genetic analyses prioritized rs11263763 and four other SNPs in high-to-moderate linkage disequilibrium as the most likely causal SNPs. Three of these SNPs map to the extended HNF1B promoter based on chromatin marks extending from the minimal promoter region. Reporter assays demonstrated that this extended region reduces activity in combination with the minimal HNF1B promoter, and that the minor alleles of rs11263763 or rs8064454 are associated with decreased HNF1B promoter activity. Our findings provide evidence for a single signal associated with endometrial cancer risk at the HNF1B locus, and that risk is likely mediated via altered HNF1B gene expression.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Regional association and forest plots for the HNF1B locus associated with endometrial cancer: (A) Locuszoom (14) plot of the log10 P-values for association between each SNP and endometrial cancer for the meta-analysis of the iCOGS fine-mapping dataset, and ANECS, SEARCH and NSECG GWAS datasets. The color of each point indicates the extent of LD with the top SNP rs11263763 (purple). Gene positions are given under the graph, and estimated recombination rates in cM/Mb are indicated by the blue line (right-hand scale). Genotyped SNPs are plotted as circles, and imputed SNPs as squares (info score ≥ 0.7 for all plotted SNPs). The small peak of signal ∼13 kb to the right of rs11263763 does not survive conditional analysis. (B) Forest plot of ORs for the GWAS and iCOGS fine-mapping datasets stratified by study and country for top SNP rs11263763 (study acronyms detailed in Supplementary Material, Table S1).
Figure 2.
Figure 2.
Association of genotypes with HNF1B expression as measured by RNA_Seq for rs11263763 (A) and rs11658063 (B), and with average HNF1B CpG island methylation for rs11263763 (C) and rs11658063 (D).
Figure 3.
Figure 3.
Genetic associations and epigenetic landscape at the HNF1B locus. (A) Enlarged image of the HNF1B intron 1 region, showing the epigenetic landscape in ENCODE cell lines. The top five likely causal SNPs are indicated in relation to marks of regulatory potential; (B) Histones H3K4Me1 (indicative of regulatory regions) and H3K4Me3 (indicative of promoters); (C) DNaseI hypersensitivity (DHS: indicative of open chromatin, with darker shading indicating stronger experimental signal) in 125 (layered) ENCODE cell lines and endometrial cancer ECC1 (DMSO and estradiol 10 m) and Ishikawa (4-OHTAM and estradiol 10 m) cell lines; (D) Transcription factor (TF) binding in 72 ENCODE cell lines; (E) Chromatin state in nine ENCODE cell lines, with the following color coding: bright red-active promoter; light red-weak promoter; purple-inactive/poised promoter; orange-strong enhancer; yellow-weak enhancer; blue-insulator; dark green-transcriptional transition; light green-weak transcribed; dark gray-repressed/heterochromatin; (F) HNF1B CpG island. The solid red box represents the extended promoter region, and the hatched box the minimal promoter region.
Figure 4.
Figure 4.
Luciferase reporter assays in endometrial cell lines demonstrate that SNPs rs11263763 and rs8064454 reduce the extended HNF1B promoter activity. The minimal HNF1B (Min prom) or extended HNF1B (Ext prom) promoters were cloned upstream of a luciferase reporter. An Ext prom construct containing either the wild-type haplotype or minor alleles of rs11263763, rs11651052 or rs8064454 were also generated. Cells were transiently transfected with each of these constructs and assayed for luciferase activity after 48 h. Error bars denote standard error of the mean (SEM) from three independent experiments. P-values were determined with a two-tailed t test (*P < 0.05, **P < 0.01, ***P < 0.001).

Similar articles

Cited by

  • Risk of postmenopausal hormone therapy and patient history factors for the survival rate in women with endometrial carcinoma.
    Hein A, Schneider MO, Renner SK, Fasching PA, Fiessler C, Titz S, Hartmann A, Beckmann MW, Thiel FC. Hein A, et al. Arch Gynecol Obstet. 2020 Jan;301(1):289-294. doi: 10.1007/s00404-019-05414-3. Epub 2019 Dec 19. Arch Gynecol Obstet. 2020. PMID: 31858234
  • Expression, Epigenetic and Genetic Changes of HNF1B in Endometrial Lesions.
    Němejcová K, Tichá I, Kleiblová P, Bártů M, Cibula D, Jirsová K, Dundr P. Němejcová K, et al. Pathol Oncol Res. 2016 Jul;22(3):523-30. doi: 10.1007/s12253-015-0037-2. Epub 2015 Dec 19. Pathol Oncol Res. 2016. PMID: 26685938
  • Network-directed cis-mediator analysis of normal prostate tissue expression profiles reveals downstream regulatory associations of prostate cancer susceptibility loci.
    Larson NB, McDonnell SK, Fogarty Z, Larson MC, Cheville J, Riska S, Baheti S, Weber AM, Nair AA, Wang L, O'Brien D, Davila J, Schaid DJ, Thibodeau SN. Larson NB, et al. Oncotarget. 2017 Sep 8;8(49):85896-85908. doi: 10.18632/oncotarget.20717. eCollection 2017 Oct 17. Oncotarget. 2017. PMID: 29156765 Free PMC article.
  • Identification of nine new susceptibility loci for endometrial cancer.
    O'Mara TA, Glubb DM, Amant F, Annibali D, Ashton K, Attia J, Auer PL, Beckmann MW, Black A, Bolla MK, Brauch H, Brenner H, Brinton L, Buchanan DD, Burwinkel B, Chang-Claude J, Chanock SJ, Chen C, Chen MM, Cheng THT, Clarke CL, Clendenning M, Cook LS, Couch FJ, Cox A, Crous-Bous M, Czene K, Day F, Dennis J, Depreeuw J, Doherty JA, Dörk T, Dowdy SC, Dürst M, Ekici AB, Fasching PA, Fridley BL, Friedenreich CM, Fritschi L, Fung J, García-Closas M, Gaudet MM, Giles GG, Goode EL, Gorman M, Haiman CA, Hall P, Hankison SE, Healey CS, Hein A, Hillemanns P, Hodgson S, Hoivik EA, Holliday EG, Hopper JL, Hunter DJ, Jones A, Krakstad C, Kristensen VN, Lambrechts D, Marchand LL, Liang X, Lindblom A, Lissowska J, Long J, Lu L, Magliocco AM, Martin L, McEvoy M, Meindl A, Michailidou K, Milne RL, Mints M, Montgomery GW, Nassir R, Olsson H, Orlow I, Otton G, Palles C, Perry JRB, Peto J, Pooler L, Prescott J, Proietto T, Rebbeck TR, Risch HA, Rogers PAW, Rübner M, Runnebaum I, Sacerdote C, Sarto GE, Schumacher F, Scott RJ, Setiawan VW, Shah M, Sheng X, Shu XO, Southey MC, Swerdlow AJ, Tham E, Trovik J, Turman C, Tyrer JP, Vachon C, VanDen Berg D, Vanderstichele A, Wang Z, Webb PM, Wentzensen N, Wern… See abstract for full author list ➔ O'Mara TA, et al. Nat Commun. 2018 Aug 9;9(1):3166. doi: 10.1038/s41467-018-05427-7. Nat Commun. 2018. PMID: 30093612 Free PMC article.
  • Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study.
    Telomeres Mendelian Randomization Collaboration; Haycock PC, Burgess S, Nounu A, Zheng J, Okoli GN, Bowden J, Wade KH, Timpson NJ, Evans DM, Willeit P, Aviv A, Gaunt TR, Hemani G, Mangino M, Ellis HP, Kurian KM, Pooley KA, Eeles RA, Lee JE, Fang S, Chen WV, Law MH, Bowdler LM, Iles MM, Yang Q, Worrall BB, Markus HS, Hung RJ, Amos CI, Spurdle AB, Thompson DJ, O'Mara TA, Wolpin B, Amundadottir L, Stolzenberg-Solomon R, Trichopoulou A, Onland-Moret NC, Lund E, Duell EJ, Canzian F, Severi G, Overvad K, Gunter MJ, Tumino R, Svenson U, van Rij A, Baas AF, Bown MJ, Samani NJ, van t'Hof FNG, Tromp G, Jones GT, Kuivaniemi H, Elmore JR, Johansson M, Mckay J, Scelo G, Carreras-Torres R, Gaborieau V, Brennan P, Bracci PM, Neale RE, Olson SH, Gallinger S, Li D, Petersen GM, Risch HA, Klein AP, Han J, Abnet CC, Freedman ND, Taylor PR, Maris JM, Aben KK, Kiemeney LA, Vermeulen SH, Wiencke JK, Walsh KM, Wrensch M, Rice T, Turnbull C, Litchfield K, Paternoster L, Standl M, Abecasis GR, SanGiovanni JP, Li Y, Mijatovic V, Sapkota Y, Low SK, Zondervan KT, Montgomery GW, Nyholt DR, van Heel DA, Hunt K, Arking DE, Ashar FN, Sotoodehnia N, Woo D, Rosand J, Comeau ME, Brown WM, Silverman EK, Hokanson JE,… See abstract for full author list ➔ Telomeres Mendelian Randomization Collaboration, et al. JAMA Oncol. 2017 May 1;3(5):636-651. doi: 10.1001/jamaoncol.2016.5945. JAMA Oncol. 2017. PMID: 28241208 Free PMC article.

References

    1. Tavassoli F.A., Stratton M.R. Tumors of the Breast and Female Genital Organs. Lyon: IARC Press; 2003.
    1. Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73. - PMC - PubMed
    1. Spurdle A.B., Thompson D.J., Ahmed S., Ferguson K., Healey C.S., O'Mara T., Walker L.C., Montgomery S.B., Dermitzakis E.T., Fahey P., et al. Genome-wide association study identifies a common variant associated with risk of endometrial cancer. Nat. Genet. 2011;43:451–454. - PMC - PubMed
    1. Gudmundsson J., Sulem P., Steinthorsdottir V., Bergthorsson J.T., Thorleifsson G., Manolescu A., Rafnar T., Gudbjartsson D., Agnarsson B.A., Baker A., et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat. Genet. 2007;39:977–983. - PubMed
    1. Sun J., Zheng S.L., Wiklund F., Isaacs S.D., Purcell L.D., Gao Z., Hsu F.C., Kim S.T., Liu W., Zhu Y., et al. Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat. Genet. 2008;40:1153–1155. - PMC - PubMed

Publication types

MeSH terms

Grants and funding